Last Update 08 Apr 26

CAH: Specialty Expansion And Distribution Onboarding Will Support Future Upside

Analysts have nudged their consolidated price targets for Cardinal Health, including moves such as Evercore ISI's $20 trim along with multiple recent increases from firms like Barclays, Wells Fargo, Morgan Stanley, Baird, Mizuho, TD Cowen, BofA, Leerink and Citi, as they point to broad strength across the business and updated models after guidance changes.

Analyst Commentary

Recent research updates around Cardinal Health cluster around a broadly constructive tone, with most firms adjusting their models after the latest guidance changes and commentary on business trends. At the same time, there are pockets of caution around specific business lines and execution on newer initiatives.

Bullish Takeaways

Bullish analysts point to guidance being raised several times since the June investor day and describe this pattern as evidence of strength across the business. They see this as supportive for higher valuation assumptions in their models.
Several price target increases are tied to what analysts describe as strength across Cardinal Health's operations. Updated estimates reflect confidence in the company’s ability to execute on its current plan rather than relying on more aggressive growth assumptions.
The build out of specialty assets and the resiliency of the core distribution business are highlighted as key supports for earnings quality. Some analysts cite these areas as reasons to expect Cardinal Health to sustain or improve its earnings power over time.
Bullish analysts also point to the onboarding of distribution from recently acquired MSO assets as a potential source of additional volume and contribution to future estimates. They factor this into higher price targets and constructive ratings.

Bearish Takeaways

Even within generally positive reports, some analysts explicitly flag ongoing concerns around the GMPD businesses. They suggest that weaker performance or execution risk in these segments could weigh on consolidated results and justify more cautious valuation multiples.
One bullish research note acknowledges that guidance and consensus estimates are still in what is described as a reasonable place. This can be read as a reminder that expectations are not low and that any execution slip could pressure both the stock and future estimate revisions.
Although some firms talk about room for upside, this is framed against already raised guidance and higher targets. This may limit the margin for error if Cardinal Health does not deliver in line with these updated assumptions.
The recent $20 reduction in a price target by one major firm shows that not all model changes are in the same direction. This underscores that there is still debate around the appropriate valuation level given the mix of strengths and areas of concern inside the portfolio.

What's in the News

Cardinal Health is expanding Actinium-225 production capacity at its Center for Theranostics Advancement in Indianapolis, adding a high-capacity production line to its Drug Master File to supply cGMP-compliant Ac-225 for investigational and potential future commercial therapies, with weekly output reported at roughly 4x the level announced at the end of 2024 (Key Developments).
The company reports that its Ac-225 output currently supports more than 15 clinical trials worldwide and multiple regulatory applications for cGMP-compliant Ac-225, highlighting broad use by pharmaceutical developers of targeted alpha therapies (Key Developments).
From October 1, 2025 to December 31, 2025, Cardinal Health repurchased 2,318,688 shares (0.97%) for US$426.96m, bringing total repurchases under the June 8, 2023 program to 10,791,545 shares (4.48%) for US$1,483.96m (Key Developments).
AOP Health US reports that Rapiblyk (landiolol), a critical care therapy for rapid heart rate conditions, is now more widely available across the United States through Cardinal and other distributors, giving hospitals and health systems additional purchasing options (Key Developments).
Cardinal Health is included on a list of companies scheduled to report earnings before the market open, drawing attention from traders who track upcoming reports for potential catalysts (Periodicals).

Valuation Changes

Fair Value: Model fair value stays unchanged at $249.60, with no shift in the underlying fair value estimate.
Discount Rate: The discount rate remains effectively steady at 6.98%, indicating no material adjustment to the required return used in the model.
Revenue Growth: Revenue growth assumption is essentially unchanged at about 9.04%, with only a minimal numerical refinement in the updated model.
Net Profit Margin: Net profit margin input holds steady at roughly 0.82%, with the updated figure showing only a very small rounding difference.
Future P/E: The future P/E multiple remains consistent at about 26.44x, reflecting no practical change in the valuation multiple applied to forward earnings.

6 views

Key Takeaways

Growth in pharmaceuticals and specialty distribution is driven by demographic trends, with diversification into specialty and home healthcare strengthening future earnings potential.
Efficiency gains from automation and portfolio optimization are expected to improve margins, cash flow, and profit resilience amid ongoing healthcare industry changes.
Increasing regulatory pressures, competitive threats, customer dependence, and evolving reimbursement risks could compress margins and constrain Cardinal Health's long-term growth prospects.

Catalysts

About Cardinal Health

Operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally.What are the underlying business or industry changes driving this perspective?

Cardinal Health is well-positioned to benefit from increasing global demand for pharmaceuticals and medical supplies driven by an aging population and the rising prevalence of chronic diseases, which is leading to robust pharmaceutical volumes and consistent revenue growth in core and specialty distribution-positively impacting future top-line revenue.
The company's investments in automation, advanced supply chain technology, and new distribution centers are expected to deliver long-term operational efficiencies and cost savings, supporting improved net margins and free cash flow as healthcare shifts to value-based and outpatient models.
Strategic expansion into higher-margin specialty businesses, including acquisitions in multi-specialty MSO platforms (e.g., Solaris Health), specialty pharma, and biopharma solutions, should accelerate long-term profit growth, diversify revenue streams, and enhance overall earnings resilience.
The strong performance and continued investment in Other growth businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics aligns with the growing trend of outpatient and home healthcare-underpinning diversified revenue growth and supporting margin expansion.
Ongoing efforts to optimize the generic drug portfolio and scale Cardinal Health-branded medical products are yielding higher profitability versus branded counterparts and are expected to further enhance gross profit and operating margins, reinforcing long-term earnings growth.

Cardinal Health Earnings and Revenue Growth

Cardinal Health Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cardinal Health's revenue will grow by 9.0% annually over the next 3 years.
Analysts assume that profit margins will increase from 0.7% today to 0.8% in 3 years time.
Analysts expect earnings to reach $2.6 billion (and earnings per share of $11.51) by about April 2029, up from $1.7 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.5x on those 2029 earnings, down from 30.1x today. This future PE is greater than the current PE for the US Healthcare industry at 22.5x.
Analysts expect the number of shares outstanding to decline by 1.41% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing government regulation and pricing scrutiny, as referenced by the company managing through "regulatory uncertainty" and "the implementation of tariffs," could compress distribution margins and impact net margins and earnings over the long term.
Heightened competition from peers and potential loss or expiration of major customer contracts, as seen in the "previously announced customer contract expiration," could limit future revenue growth and pressure operating earnings.
Ongoing tariff headwinds and global supply chain risks remain substantial, with GMPD segment guidance assuming a "$50 million to $75 million headwind to our results in fiscal '26 from tariffs," while further volatility could drive increased costs and impact consolidated margins and net income.
Increasing consolidation and vertical integration among healthcare providers, payers, and retailers-combined with Cardinal's dependence on major customer relationships highlighted by the impact of contract expirations-may compress revenue streams and erode gross profit over time.
Potential reimbursement changes and government bidding programs, such as referenced "potential changes in the reimbursement environment" and "competitive bidding coming back," specifically in the at-Home Solutions segment, could reduce top-line growth and profitability within key business lines.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $249.6 for Cardinal Health based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $200.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $317.2 billion, earnings will come to $2.6 billion, and it would be trading on a PE ratio of 26.5x, assuming you use a discount rate of 7.0%.
Given the current share price of $212.77, the analyst price target of $249.6 is 14.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cardinal Health?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

CAH: Core Pharmaceutical Trends And Automation Will Shape Upcoming Earnings Performance